Per Olsson Gisleskog

Managing Director and Principal Consultant | Pharmacometrics & PK/PD Modeling Expert

About

Per Olsson Gisleskog, PhD, is a pharmacometrics consultant with a long experience both in the application of advanced modelling and simulation techniques, and in their strategical use for decision making in pharmaceutical development, Dr Per Olsson Gisleskog is the founder of POG Pharmacometrics. Per was born in 1960 in Sweden. He obtained his M.Sc. in pharmacy and his PhD from the University of Uppsala. His PhD focussed on population PK/PD modelling. He has 14 years experience of pharmaceutical drug development within the industry, working for Pharmacia in Sweden and Glaxo/GSK in the UK. During this time he was responsible for pharmacokinetics, population pharmacokinetics, modelling and simulation in several therapeutic areas. He was also appointed clinical project team leader. For the last 25 years Per has been a consultant within the pharmacometric field, first at Pharsight, and after this at Exprimo, where he was a co-founder, and now at POG pharmacometrics. He is author of several original research papers in the fields of pharmacokinetic / pharmacodynamic modelling. His current research interests focus around the use of modelling and simulation approaches to provide a rational basis for decision making in drug development, and around the optimisation of dose individualisation algorithms. Per lives in London, UK.

Publications

Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus

British Journal of Clinical Pharmacology

2026

Characterization of the VHH-Fc construct rimteravimab in healthy adults and patients hospitalized for mild-to-moderate COVID-19: Two Phase 1 randomized clinical trials

PLOS Medicine

2026

Population Pharmacokinetic and Exposure‐Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma

CPT: Pharmacometrics & Systems Pharmacology

2025

Evaluation of the Effect of Loperamide on the Cardiac Repolarization Interval Using Exposure–Response Analysis

Clinical and Translational Science

2025

An exposure‐response analysis of ponesimod clinical efficacy in a randomized phase III study in patients with relapsing multiple sclerosis

CPT: Pharmacometrics & Systems Pharmacology

2022

An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis

Clinical Pharmacokinetics

2021

Nicotine Population Pharmacokinetics in Healthy Smokers After Intravenous, Oral, Buccal and Transdermal Administration

Clinical Pharmacokinetics

2020

Quantification of Radiation Injury on Neutropenia and the Link between Absolute Neutrophil Count Time Course and Overall Survival in Nonhuman Primates Treated with G-CSF

Pharmaceutical Research

2020

Prediction of Survival Benefit of Filgrastim in Adult and Pediatric Patients With Acute Radiation Syndrome

Clinical and Translational Science

2020

Bridging adults and paediatrics with secondary hyperparathyroidism receiving haemodialysis: a pharmacokinetic‐pharmacodynamic analysis of cinacalcet

British Journal of Clinical Pharmacology

2019

Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis

Clinical Pharmacokinetics

2017

Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis

CPT: Pharmacometrics & Systems Pharmacology

2016

Rilotumumab Exposure–Response Relationship in Patients with Advanced or Metastatic Gastric Cancer

Clinical Cancer Research

2015

Population Pharmacokinetics of Rilotumumab, a Fully Human Monoclonal Antibody Against Hepatocyte Growth Factor, in Cancer Patients

Journal of Pharmaceutical Sciences

2014

Dopamine D2 Occupancy as a Biomarker for Antipsychotics: Quantifying the Relationship with Efficacy and Extrapyramidal Symptoms

The AAPS Journal

2010

Population Pharmacokinetics Meta-Analysis of Recombinant Human Erythropoietin in Healthy Subjects

Clinical Pharmacokinetics

2007

Modelling and simulation to improve decision-making in clinical development

Pharmaceutical Statistics

2005

Pharmacokinetics of Melagatran and the Effect on Ex Vivo Coagulation Time in Orthopaedic Surgery Patients Receiving Subcutaneous Melagatran and Oral Ximelagatran

Clinical Pharmacokinetics

2003

Use of Prior Information to Stabilize a Population Data Analysis

Journal of Pharmacokinetics and Pharmacodynamics

2002

Validation of a population pharmacokinetic/pharmacodynamic model for 5α-reductase inhibitors

European Journal of Pharmaceutical Sciences

1999

The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination

British Journal of Clinical Pharmacology

1999

A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α-reductase inhibitors GI198745 and finasteride

Clinical Pharmacology & Therapeutics

1998

Pharmacokinetics and testosterone suppression of a single dose of polyestradiol phosphate (Estradurin®) in prostatic cancer patients

The Prostate

1996

Pharmacokinetics of a 16-Hour Transdermal Nicotine Patch

Clinical Drug Investigation

1996

The Disposition of a New Drug Propellant (HFA 134a) in Humans Studied by Fluorine-18 Labelling and Whole-Body γ-Counting

PET for Drug Development and Evaluation

1995

Disposition of inhaled 1,1,1,2-tetrafluoroethane (HFA134A) in healthy subjects and in patients with chronic airflow limitation. Measurement by 18F-labeling and whole-body gamma-counting.

Drug Metabolism and Disposition

1995

Efficacy of a Topical Nasal Decongestant in Different Formulations: the Effect of Viscosity

Acta Oto-Laryngologica

1992

Pharmacokinetics of Nicotine after Intranasal Administration

Effects of Nicotine on Biological Systems

1991

Intravenous nicotine retards transdermal absorption of nicotine: Evidence of blood flow–limited percutaneous absorption

Clinical Pharmacology and Therapeutics

1992

Absolute bioavailability of nicotine applied to different nasal regions

European Journal of Clinical Pharmacology

1991

Education

Uppsala universitet

PhD, Pharmaceutical Sciences / December, 1999

Uppsala University

PhD, Pharmaceutical Sciences / January, 1999

Uppsala universitet

PhD, Pharmaceutical Sciences / December, 1999

Uppsala University

PhD, Pharmaceutical Sciences / January, 1999

Faculty of Pharmacy Uppsala University Sweden

Ph.D. in biopharmaceutics and pharmacokinetics, Biopharmaceutics and Pharmacokinetics / 1999

Faculty of Pharmacy Uppsala University Sweden

M.Sc. in pharmaceutical sciences, Pharmaceutical Sciences (specialisation in pharmacokinetics and biopharmaceutics) / 1985

Experience

POG Pharmacometrics

Managing Director, Principal Consultant / August, 2018 — Present

SGS Exprimo NV

Principal Consultant / July, 2012 — August, 2018

Principal Consultant / January, 2012 — January, 2018

Founding Partner and Scientific consultant developing the group and providing population PK PKPD and endpoint modelling and clinical trial simulation services to all stages of drug development.

Exprimo NV

Principal Consultant / September, 2002 — June, 2012

Pharsight

Senior Consultant / January, 1999 — January, 2002

Glaxo/GlaxoWellcome,Middlesex, UK

Pharmacokineticist / February, 1993 — December, 1999

Leo

Pharmacokineticist / January, 1988 — January, 1993

POG Pharmacometrics Limited

Managing Director and Principal Consultant / January, 2018 — January

Managing director and scientific consultant providing population PK PKPD and endpoint and AE exposure-response modelling and clinical trial simulation services across a wide range of therapeutic areas to all stages of drug development.

Exprimo NV Belgium

Director / January, 2005 — January, 2012

Director and scientific consultant providing population PK PKPD and endpoint modelling and clinical trial simulation services to all stages of drug development.

Exprimo Consulting LLP UK

Partner / January, 2002 — January, 2005

Founding Partner and scientific consultant developing the group and providing pharmacometrics consulting services.

Pharsight Corporation UK

Senior Consultant / January, 2000 — January, 2002

Scientific consultant performing clinical PKPD modelling disease endpoint modelling and clinical trial simulation across a wide range of therapeutic areas for pharmaceutical industry clients.

Glaxo GlaxoWellcome UK

Principal Pharmacokineticist / Senior / Clinical Pharmacokineticist / January, 1993 — January, 1999

Pharmacokineticist responsible for cardiovascular anti-inflammatory and respiratory therapeutic areas. Project pharmacokineticist and project team member in 10 clinical projects. Population PK and PKPD modelling simulation allometric scaling study design data analysis and interpretation. Responsible for internal PK software development. Clinical project team leader.

Pharmacia-Leo Sweden

Pharmacokineticist / January, 1988 — January, 1993

Project pharmacokineticist and project team member in smoking cessation and cancer therapeutic areas from pre-clinical to phase IV. PK and PKPD modelling. Designing running monitoring analysing and reporting of phase III studies. Author of PK parts of NDA and drug label.

Leo Sweden

Pharmaceutical development scientist / January, 1985 — January, 1987

Pharmaceutical development scientist.

Join Per on NotedSource!

Join Now

At NotedSource, we believe that professors, post-docs, scientists and other researchers have deep, untapped knowledge and expertise that can be leveraged to drive innovation within companies. NotedSource is committed to bridging the gap between academia and industry by providing a platform for collaboration with industry and networking with other researchers.

For industry, NotedSource identifies the right academic experts in 24 hours to help organizations build and grow. With a platform of thousands of knowledgeable PhDs, scientists, and industry experts, NotedSource makes connecting and collaborating easy.

For academic researchers such as professors, post-docs, and Ph.D.s, NotedSource provides tools to discover and connect to your colleagues with messaging and news feeds, in addition to the opportunity to be paid for your collaboration with vetted partners.